BarbriSFCourseDetails

Course Details

This CLE course will analyze various ways in which risks associated with the COVID-19 pandemic are currently being addressed in M&A transactions. The panel discussion will include a discussion regarding the latest M&A litigation in the wake of COVID-19 and key provisions such as MAE clauses, operating covenants, and reps and warranties; financing concerns; and due diligence.

Faculty

Description

Uncertainty created by the novel coronavirus has impacted all aspects of M&A transactions. Valuation and deal pricing have become more difficult, resulting in greater reliance on contractual provisions. Buyers who executed deals before the COVID-19 outbreak may seek to renegotiate deal terms or try to get out of deals altogether, placing greater importance on pre-closing operating covenants.

Acquisition financing has also become more difficult, and deals requiring financing are taking longer to close. Financing terms are evolving to address the risks associated with COVID-19, and other deal terms are being revised in light of the new financing risk.

MAE clauses should be reconsidered in light of specific metrics, timelines, and deadlines for events that could trigger an MAE. Reps and warranties should also be expanded to address the current and future impact of the outbreak on the target, its key customers, and key suppliers.

Listen as our authoritative panel discusses the coronavirus epidemic's issues and how they are currently being addressed in M&A transactions.

Outline

  1. Addressing COVID-19 in acquisition agreements
    1. Financing contingencies
    2. Operating covenants
    3. Representations and warranties
    4. MAE clauses
  2. Due diligence and deal process

Benefits

The panel will review these and other key issues:

  • What should buyers and sellers do to protect their interests in deals that are in process as the COVID-19 epidemic progresses?
  • What due diligence matters have become more important since the outbreak?
  • How has COVID-19 impacted valuation considerations and price adjustments?
  • How has it affected operating covenants and reps and warranties?